Biographical Information Regarding Directors and Executive Officers
DR. ELAZAR RABBANI, Ph.D. is an Enzo Biochem founder and has served as the Company's Chairman of the Board and Chief Executive Officer since its inception in 1976 and Secretary since November 25, 2009. Dr. Rabbani has authored numerous scientific publications in the field of molecular biology, in particular, nucleic acid labeling and detection. He is also the lead inventor of many of the Company's pioneering patents covering a wide range of technologies and products. Dr. Rabbani received his Bachelor of Arts degree from New York University in Chemistry and his Ph.D. in Biochemistry from Columbia University. He is a member of the American Society for Microbiology.
BARRY W. WEINER, President and a founder of Enzo Biochem. He has served as the Company's President since 1996, and previously held the position of Executive Vice President. Before his employment with Enzo Biochem, he worked in several managerial and marketing positions at the Colgate Palmolive Company. Mr. Weiner is a member of the New York Biotechnology Association. He received his Bachelor of Arts degree in Economics from New York University and a Master of Business Administration in Finance from Boston University.
DAVID BENCH, Chief Financial Officer for Enzo Biochem, has been employed with the company since 2019. Mr. Bench was previously Chief Financial Officer of ELLKAY, LLC, a healthcare information technology company servicing diagnostic laboratories, electronic medical record providers, payors, hospital/health systems and ambulatory practices. Mr. Bench has served as President of DBC Group, LLC, an advisory and consulting firm working with emerging public companies and as an investment banker at Arete Wealth Management, covering the telecommunications, media and technology industries. Earlier in his career Mr. Bench worked at the investment banking firms of Lazard and Arnhold and S. Bleichroeder. He received his B.A. in Economics and a Masters in International Economics and Finance, both from Brandeis University.
KARA CANNON, Chief Commercial Officer, has been employed with the Company since 2011 and is responsible for strategic and tactical marketing, Sales, Manufacturing and general management of the operations . Ms. Cannon previously held executive positions at Pall Corporation, where she focused on commercial operations within the areas of diagnostics, biotechnology and biosciences. She has also held marketing and technical positions at Dynal Biotech (now ThermoFisher Scientific). She has had extensive experience in the marketing and selling of innovative platforms for the diagnostics markets, as well as, the development and execution of strategic plans for the growth and sustainability of diagnostic-related businesses. Ms. Cannon holds a BA from Franklin and Marshall College.
DIETER SCHAPFEL, MD, Chief Medical Officer, has been employed with the Company since 2012, initially as a consulting pathologist. Dr. Schapfel served as Medical Director of Pathology at Southside Hospital – North Shore/Long Island Jewish Health System from 2006 to 2012. Dr. Schapfel served as a staff pathologist at Huntington Hospital from January 2004 to June 2006. Dr. Schapfel served as Director of Pathology and Medical Affairs and the College of American Pathologists Director of Pathology, Dublin, Ireland and Farmingdale, NY for Icon Laboratories from February 2002 to October 2003. Dr. Schapfel is a graduate of the State University of New York at Stony Brook, College of Medicine, where he also served his residency. He is a diplomat of the American Board of Pathology with certification in Anatomic and Clinical Pathology and is also a diplomat of The National Board of Medical Examiners.
FABIAN BLANK, has been a director of the company since February 2020. Mr. Blank is currently an independent non-executive director of Georgia Healthcare Group PLC and non-executive chairman of Recover Health Ltd. He has extensive experience as a senior healthcare executive in various sectors of the healthcare industry. He is a former partner at McKinsey, with a total tenure of 13 years, and was CEO and co-owner of the Meduna Klinik Group that was sold to PE. Mr. Blank received his graduate business management degree from HHL Leipzig Graduate School of Management and completed additional studies at University of Trier, Boston University, and ESADE in Barcelona, Spain.
PETER J. CLEMENS, IV, has been a director of the company since February 2020. Mr. Clemens is currently the Director of Vituro Health and Chairman of the Samford University Board of Overseers. He has a distinguished career in senior healthcare financial roles, and he has served as the CFO of Caremark and subsequently Surgical Care Affiliates. He has previously served on the board of DSI Renal, a privately owned dialysis company that was sold to Fresenius in September 2011. Mr. Clemens received his Bachelor’s degree from Samford University and an MBA in Finance from Vanderbilt University.
REBECCA FISCHER, was appointed as an Independent Director of the Company and has agreed to serve on the Audit, Compensation and Nominating/Governance Committees. Ms. Fischer is currently the Chief Financial Officer of NYC Health + Hospitals / Bellevue, a position she has held since 2017. She is directly involved in guiding Bellevue and its leaders through complex government and private reimbursement practices and is responsible for all budgeting, affiliation management, accounts receivable, and grant management functions for the hospital. Ms. Fischer began her career at Bellevue as Associate Director in 2003, became Associate Executive Director in 2011, and was promoted to Deputy CFO in 2016. Her prior experience includes positions at New York Presbyterian Hospital, Columbia University Medical Center, the Center for State Health Policy at Rutgers University, and the New York City Office of Management and Budget. Ms. Fischer received her undergraduate degree cum laude from Cornell University and her Master of Public Administration in Health Policy and Management from New York University, where she was a recipient of the Robert F. Wagner, Jr. Fellowship.
DOV PERLYSKY, has been a Director of the Company since September 2012 and since January 17, 2013 has served on the Audit, Nominating/Governance and Audit Committees. He currently serves as Compensation Committee Chairman. Mr. Perlysky has served as a member of the board of directors of Pharma-Bio Serv, Inc. since 2004 and as a member of the board of directors of Highlands State Bank since 2010. Mr. Perlysky has also been the managing member of Nesher, LLC, a private investment firm, since 2000 and a director of Engex, Inc., a closed-end mutual fund, since 1999. From 1998 until 2002, Mr. Perlysky was a vice president in the private client group of Laidlaw Global Securities, a registered broker-dealer. Mr. Perlysky received his B.S. in Mathematics and Computer Science from the University of Illinois in 1985 and a Masters in Management from the J.L. Kellogg School of Management of Northwestern University in 1991.